Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study Assessing the Efficacy, Safety and Pharmacokinetics of Alpelisib in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)

NCT06997588 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT06997588
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06997588 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study Assessing the Efficacy, Safety and Pharmacokinetics of Alpelisib in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)
Lead sponsor
Novartis Pharmaceuticals
Phase
Phase 2
Overall status
Recruiting
Start date
October 9, 2025
Completion date
June 18, 2031
Enrollment
140 (estimated)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

pik3ca-related overgrowth spectrum (pros)